Author

B. G. Lui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 6 Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 4 Research Focus:drug response / drug discovery· 3 Organism:non-human primate· 2 Research Focus:benchmarking· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

A. Muik· 6 shared A.-K. Wallisch· 5 shared K. Grikscheit· 4 shared M. Bacher· 4 shared O. Ozhelvaci· 4 shared O. Tuereci· 4 shared S. Ciesek· 4 shared U. Sahin· 4 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

A. Muik

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T-cell recognition epitopes

A. Muik, B. G. Lui, H. Diao, Y. Fu, M. Bacher, A. Toker, J. Grosser, O. Ozhelvaci, K. Grikscheit, S. Hoehl, N. Kohmer, Y. Lustig, G. Regev-Yochay, S. Ciesek, K. Beguir, , U. Sahin

The paper examines how Omicron sublineages evade neutralizing antibodies but retain T-cell epitopes, suggesting T-cell immunity remains effective against these variants.

bioRxiv · Dec 15, 2022 · PreprintImmunology

Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, C. I. C. Couto, A. Gueler, V. Mampilli, G. J. Schmitt, J. Mottl, T. Ziegenhals, S. Fesser, J. Reinholz, F. Wernig, K.-G. Schraut, , U. Sahin

This study shows that exposure to BA.4/BA.5 spike glycoprotein enhances neutralizing antibody breadth against Omicron variants in vaccinated humans and mice.

bioRxiv · Sep 21, 2022 · PreprintImmunology

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, A. Finlayson, K. Krueger, O. Ozhelvaci, K. Grikscheit, S. Hoehl, S. Ciesek, O. Tuereci, U. Sahin

The paper shows that BA.2 breakthrough infection in vaccinated individuals enhances neutralization of BA.2.12.1 and BA.4/BA.5 compared to BA.1 breakthrough infection.

bioRxiv · Aug 2, 2022Immunology

Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation

J. Quandt, A. Muik, N. Salisch, B. G. Lui, S. Lutz, K. Krueger, A.-K. Wallisch, P. Adams-Quack, M. Bacher, A. Finlayson, O. Ozhelvaci, I. Vogler, K. Grikscheit, S. Hoehl, U. Goetsch, , U. Sahin

bioRxiv · Apr 1, 2022 · PreprintImmunology

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. Gueler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, , M. R Gutman

This paper evaluates two BNT162b vaccine candidates in non-human primates, showing they are immunogenic and protect against SARS-CoV-2 infection.

bioRxiv · Dec 11, 2020 · PreprintImmunology

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

A. Vogel, I. Kanevsky, Y. Che, K. Swanson, A. Muik, M. Vormehr, L. Kranz, K. Walzer, S. Hein, A. Gueler, J. Loschko, M. Maddur, K. Tompkins, J. Cole, B. G. Lui, , Ciolin

This paper reports on a prefusion SARS-CoV-2 spike RNA vaccine that induces strong immune responses and prevents lung infection in non-human primates.

bioRxiv · Sep 8, 2020 · PreprintImmunology